- £182.62bn
- £202.55bn
- $45.81bn
- 86
- 13
- 80
- 64
REG - AstraZeneca PLC - Filing of Form 20-F with SEC
AnnouncementREG - AstraZeneca PLC - Annual Financial Report
AnnouncementREG - AstraZeneca PLC - AstraZeneca completes acquisition of Icosavax
AnnouncementREG - AstraZeneca PLC - FDA accepts Dato-DXd BLA for nonsquamous NSCLC
AnnouncementREG - AstraZeneca PLC - Tagrisso plus chemo approved in US for lung cancer
AnnouncementREG - AstraZeneca PLC - Tagrisso improved PFS in Stage III lung cancer
AnnouncementREG - AstraZeneca PLC - Final Results
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - AstraZeneca acquires Gracell
AnnouncementREG - AstraZeneca PLC - Wainua (eplontersen) granted first US FDA approval
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - AstraZeneca to acquire Icosavax
AnnouncementREG - AstraZeneca PLC - Block listing Interim Review
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Discontinuation of two CRYSTALIZE evidence trials
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Truqap approved in US for HR+ breast cancer
AnnouncementREG - AstraZeneca PLC - Update on PACIFIC-2 Phase III trial for Imfinzi
Announcement